Patents by Inventor Fumiaki Yokokawa

Fumiaki Yokokawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11597733
    Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: March 7, 2023
    Assignee: Novartis AG
    Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, Jr., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
  • Publication number: 20220073535
    Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.
    Type: Application
    Filed: June 18, 2019
    Publication date: March 10, 2022
    Inventors: Cyrille Kounde, Wei Lin Sandra Sim, Oliver Simon, Gang Wang, Hui Quan Yeo, Bryan KS Yeung, Fumiaki Yokokawa, Bin Zou
  • Publication number: 20210115065
    Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    Type: Application
    Filed: October 21, 2020
    Publication date: April 22, 2021
    Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, JR., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
  • Patent number: 10428105
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 1, 2019
    Assignee: Novartis AG
    Inventors: Martijn Fenaux, Oliver Saunders, Fumiaki Yokokawa, Weidong Zhong
  • Publication number: 20180258129
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: Martijn FENAUX, Oliver SAUNDERS, Fumiaki YOKOKAWA, Weidong ZHONG
  • Patent number: 9988416
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: June 5, 2018
    Assignee: Novartis AG
    Inventors: Martijn Fenaux, Oliver Saunders, Fumiaki Yokokawa, Weidong Zhong
  • Patent number: 9814739
    Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
  • Publication number: 20170275329
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 28, 2017
    Inventors: Martijn FENAUX, Oliver SAUNDERS, Fumiaki YOKOKAWA, Weidong ZHONG
  • Publication number: 20170112868
    Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 27, 2017
    Inventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
  • Patent number: 9556216
    Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are as defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: January 31, 2017
    Assignee: Novartis AG
    Inventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
  • Publication number: 20160289259
    Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 6, 2016
    Applicant: Novartis AG
    Inventor: Fumiaki Yokokawa
  • Publication number: 20150232501
    Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are as defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Application
    Filed: August 27, 2013
    Publication date: August 20, 2015
    Applicant: Novartis AG
    Inventors: Sampath-Kumar ANADAN, Virender Singh AULAKH, Martijn FENAUX, Xiaodong LIN, Liang MAO, Oliver SAUNDERS, Zachary Kevin SWEENEY, Fumiaki YOKOKAWA, Weidong ZHONG
  • Publication number: 20140205566
    Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: wherein R1, R2 and R3 are as defined herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 24, 2014
    Applicant: NOVARTIS AG
    Inventors: Lv LIAO, Fumiaki YOKOKAWA, Gang WANG
  • Publication number: 20140065101
    Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.
    Type: Application
    Filed: August 27, 2013
    Publication date: March 6, 2014
    Applicant: Novartis AG
    Inventor: Fumiaki Yokokawa
  • Patent number: 8497286
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 30, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8383650
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: February 26, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Publication number: 20130005770
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 3, 2013
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8178559
    Abstract: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 15, 2012
    Assignee: Novartis AG
    Inventors: Werner Breitenstein, Takeru Ehara, Claus Ehrhardt, Philipp Grosche, Yuko Hitomi, Yuki Iwaki, Takanori Kanazawa, Kazuhide Konishi, Juergen Klaus Maibaum, Keiichi Masuya, Atsuko Iwasaki, Nils Ostermann, Masaki Suzuki, Atsushi Toyao, Fumiaki Yokokawa
  • Patent number: 8163773
    Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: April 24, 2012
    Assignee: Novartis AG
    Inventors: Werner Breitenstein, Claus Erhardt, Juergen Klaus Maibaum, Nils Ostermann, Juerg Zimmermann, Keiichi Masuya, Kazuhide Konishi, Fumiaki Yokokawa, Takanori Kanazawa, Edgar Jacoby, Andreas Marzinzik, Philipp Grosche, Shimpei Kawakami
  • Patent number: 8129411
    Abstract: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I? wherein R1, R2, T, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: March 6, 2012
    Assignee: Novartis AG
    Inventors: Takeru Ehara, Philipp Grosche, Osamu Irie, Yuki Iwaki, Takanori Kanazawa, Shimpei Kawakami, Kazuhide Konishi, Muneto Mogi, Masaki Suzuki, Fumiaki Yokokawa